Guildford, UK, 14 September 2009: ReNeuron Group plc (the “Company”) is pleased to announce the appointment of Daniel Stewart & Company plc as Nominated Adviser and joint broker to the Company with immediate effect. The Company is also pleased to announce that Matrix Corporate Capital LLP has been appointed as joint broker to the Company with immediate effect.
Guildford, UK, 10 September 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed a contract with Angel Biotechnology Holdings plc (“Angel”), under which Angel will manufacture clinical-grade lots of a second-generation formulation of ReNeuron’s lead CTX stem cell line, for subsequent pre-clinical and clinical applications.
Guildford, UK, 11 August 2009: ReNeuron Group plc (LSE: RENE.L) today announces the publication of three papers in peer-reviewed journals regarding its ReN001 stem cell therapy for stroke and its lead CTX stem cell line. The CTX cell line forms the basis of ReNeuron’s principal therapeutic programmes, including the ReN001 stroke therapy.
Guildford, UK, 10 August 2009: ReNeuron Group plc (LSE: RENE.L) today announces the publication of two papers regarding pre-clinical data with its ReN003 stem cell therapy programme for diseases of the retina. Both papers relate to research conducted by Dr Michael Young and colleagues at the Schepens Eye Research Institute at Harvard Medical School, Boston, USA.
Guildford, UK, 31 July 2009: ReNeuron Group plc (LSE: RENE.L) gives notice that its Annual Report and Accounts for the year ended 31 March 2009 have been sent to shareholders, and are also now available on the Company’s website at www.reneuron.com.
Guildford, UK, 30 July 2009: ReNeuron Group plc (LSE: RENE.L) today announces that the UK Gene Therapy Advisory Committee (GTAC) has issued a Favourable Opinion subject to conditions in respect of ReNeuron’s proposed Phase I clinical trial with its ReN001 stem cell therapy for stroke. This development follows on from the earlier Provisional Opinion given by GTAC in May and is the result of further interactions between the Principal Investigator for the trial, ReNeuron and GTAC over the intervening period. GTAC acts as the national research ethics committee for gene therapy and stem cell therapy clinical trials in the UK.
Guildford, UK, 14 July 2009: ReNeuron Group plc (LSE: RENE.L) welcomes today’s launch of the “Life Sciences Blueprint” document from the Office of Life Sciences, a body created by the Government in January of this year to work with the life sciences industry, academia and the NHS in putting together a package of measures to transform the operating environment for life sciences companies in the UK.
Guildford, UK, 8 July 2009: ReNeuron Group plc (LSE: RENE.L) today announces the publication in Stem Cells and Development 1 of pre-clinical data concerning the potential mechanism of action of ReNeuron’s lead CTX neural stem cell line in stroke and neurodegenerative diseases. The work was conducted by Professor Paul Sanberg, Dr Carmelina Gemma and colleagues at the Center of Excellence for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine (part of USF Health), Tampa, Florida, USA. The data were originally presented in conference in the US earlier this year.
ReNeuron announces preliminary results for the Group for the year ended 31 March 2009.
Guildford, UK, 9 June 2009: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed a contract with Angel Biotechnology Holdings plc (“Angel”), under which Angel will manufacture clinical-grade ReN001 stem cell lots for ReNeuron’s Phase I clinical trial with its ReN001 therapy in disabled stroke patients. Regulatory approval for this trial was granted earlier this year.
